Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

Who cannot join

• 1. History of treatment for active or latent tuberculosis infection or history of positive PPD. 2. History or evidence of active tuberculosis. 3. Has received vaccination or immunotherapy with a BCG product at any time prior to randomization. 4. Shared a residence within the last year prior to randomization with an individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis. 5. Received a tuberculin skin test within 3 months (90 days) prior to the time of randomization through study day 85. 6. Body temperature >/=100.4°F (>/=38°C) or acute illness within 3 days before study injection days (subject may be rescheduled). 7. A positive serum or urine pregnancy test at screening or within 24 hours prior to study injection, women who are planning to become pregnant, or women who are breastfeeding. At screening visit only If female of childbearing potential as defined in Inclusion Criterion #2 from 28 days prior to entering the study until 90 days after the final study injection 8. Immunosuppression as a result of an underlying illness or treatment or use of anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36 months. 9. An active neoplastic disease (excluding nonmelanoma skin cancer) or a history of any hematologic malignancy. defined as neoplastic disease or treatment for neoplastic disease within the past 5 years 10. A history of autoimmune disease (systemic lupus, rheumatoid arthritis, scleroderma, polyarteritis, thyroiditis, etc). 11. Used an immunosuppressive or immunomodulatory drug for 2 or more consecutive weeks within 6 months prior to the first study injection (nasal and topical steroids are allowed). such as >0.5 mg/kg/day or >/=20 mg total dose/day of prednisone orally or >800 µg of inhaled beclomethasone 12. A diagnosis of schizophrenia, bipolar disease, or history of hospitalization for a psychiatric condition or previous suicide attempt. 13. A history of treatment for any other psychiatric disorder in the past 3 years that increases the risk to the subject in the opinion of the investigator. 14. A history of receiving immunoglobulin or other blood product within 3 months prior to enrollment through study day 85. 15. Received or plan to receive any live licensed vaccines within 4 weeks or inactivated licensed vaccines within 2 weeks of any study injection. 16. An acute or chronic medical condition that would render study injections unsafe or would interfere with the evaluation of responses or is not generally seen in healthy, normal subjects. in the opinion of the investigator NOTE: This includes, but is not limited to, known cardiac disease, pulmonary disease, liver disease, renal disease, unstable or progressive neurological disorders, diabetes mellitus, and transplant recipients. 17. History of anaphylaxis or severe allergic reaction to vaccines or history of allergic reaction to eggs, kanamycin-related antibiotics or other components in the antigen and adjuvant formulations. 18. Receipt of an experimental agent within 1 month before study injections in this study or expectation to receive an experimental agent during the 15-month study period. vaccine, drug, biologic, device, blood product, or medication 19. Any condition that would place the subject at an unacceptable injury risk, render him/her unable to meet the requirements of the protocol, or that may interfere with successful study completion. in the opinion of the investigator 20. A history of alcohol or drug abuse during the previous 1 year or chronic marijuana abuse or any other illicit drug use. for example, daily excessive alcohol use or frequ ent binge drinking as determined by the investigator 21. Presence of tattoos that would preclude evaluation of the injection site.